Results from a study presented at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that when antibodies develop in response to the biological treatment infliximab, they cross-react with the biosimilar of infliximab.These findings suggest that antibody-positive patients being treated with infliximab should not be switched to its biosimilar, since these antibodies will interact with the biosimilar and potentially lead to a loss of response.

Click here for more.